BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 32612606)

  • 1. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
    Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Sosman JA; Zhang B; Wu JD; Miller SD; Meeks JJ; Lukas RV; Wyatt E; Doglio L; Schiltz GE; McCusker RH; Wainwright DA
    Front Immunol; 2020; 11():1185. PubMed ID: 32612606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.
    Hosseinalizadeh H; Mahmoodpour M; Samadani AA; Roudkenar MH
    Med Oncol; 2022 Jun; 39(9):130. PubMed ID: 35716323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of IDO in brain tumor immunotherapy.
    Zhai L; Lauing KL; Chang AL; Dey M; Qian J; Cheng Y; Lesniak MS; Wainwright DA
    J Neurooncol; 2015 Jul; 123(3):395-403. PubMed ID: 25519303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
    Soliman H; Mediavilla-Varela M; Antonia S
    Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
    Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
    Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
    Ladomersky E; Zhai L; Lauing KL; Bell A; Xu J; Kocherginsky M; Zhang B; Wu JD; Podojil JR; Platanias LC; Mochizuki AY; Prins RM; Kumthekar P; Raizer JJ; Dixit K; Lukas RV; Horbinski C; Wei M; Zhou C; Pawelec G; Campisi J; Grohmann U; Prendergast GC; Munn DH; Wainwright DA
    Clin Cancer Res; 2020 Oct; 26(19):5232-5245. PubMed ID: 32546647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
    Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
    Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma.
    Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Nguyen B; Genet M; Kim M; Chen P; Mi X; Wu JD; Schipma MJ; Wray B; Griffiths J; Unwin RD; Clark SJ; Acharya R; Bao R; Horbinski C; Lukas RV; Schiltz GE; Wainwright DA
    Clin Cancer Res; 2021 Dec; 27(23):6514-6528. PubMed ID: 34479957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
    Brochez L; Chevolet I; Kruse V
    Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
    Amobi A; Qian F; Lugade AA; Odunsi K
    Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDO1 in cancer: a Gemini of immune checkpoints.
    Zhai L; Ladomersky E; Lenzen A; Nguyen B; Patel R; Lauing KL; Wu M; Wainwright DA
    Cell Mol Immunol; 2018 May; 15(5):447-457. PubMed ID: 29375124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
    Katz JB; Muller AJ; Prendergast GC
    Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-gamma and tumor necrosis factor-alpha.
    Däubener W; Remscheid C; Nockemann S; Pilz K; Seghrouchni S; Mackenzie C; Hadding U
    Eur J Immunol; 1996 Feb; 26(2):487-92. PubMed ID: 8617321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma.
    Mohapatra SR; Sadik A; Tykocinski LO; Dietze J; Poschet G; Heiland I; Opitz CA
    Front Immunol; 2019; 10():2762. PubMed ID: 31866995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
    Selvan SR; Dowling JP; Kelly WK; Lin J
    Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways.
    Le Rond S; Gonzalez A; Gonzalez AS; Carosella ED; Rouas-Freiss N
    Immunology; 2005 Nov; 116(3):297-307. PubMed ID: 16236119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
    Muller AJ; Malachowski WP; Prendergast GC
    Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
    Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS
    Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.
    Ricciuti B; Leonardi GC; Puccetti P; Fallarino F; Bianconi V; Sahebkar A; Baglivo S; Chiari R; Pirro M
    Pharmacol Ther; 2019 Apr; 196():105-116. PubMed ID: 30521884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.
    Prendergast GC; Smith C; Thomas S; Mandik-Nayak L; Laury-Kleintop L; Metz R; Muller AJ
    Cancer Immunol Immunother; 2014 Jul; 63(7):721-35. PubMed ID: 24711084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.